ArticleAntimicrobial agents and chemotherapy2006
Rapid degradation of oseltamivir phosphate in clinical samples by plasma esterases.
Article in Antimicrobial agents and chemotherapy, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 43 citations in OpenAlex.
- Effects of alcohol on human carboxylesterase drug metabolism.Clinical pharmacokinetics · 2015Trial
- Pharmacokinetics and tolerability of oseltamivir combined with probenecid.Antimicrobial agents and chemotherapy · 2008Trial
- Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza.PloS one · 2008Trial
- Electrochemical Acetylcholinesterase Sensors for Anti-Alzheimer's Disease Drug Determination.Biosensors · 2024Review
- Metabolism and disposition of oseltamivir (OS) in rats, determined by immunohistochemistry with monospecific antibody for OS or its active metabolite oseltamivir carboxylate (OC): A possibility of transporters dividing the drugs' excretion into the bile and kidney.Pharmacology research & perspectives · 2020Article
- Pharmacokinetic Modeling and Monte Carlo Simulation to Predict Interindividual Variability in Human Exposure to Oseltamivir and Its Active Metabolite, Ro 64-0802.The AAPS journal · 2017Article
- Bench to bed evidences for pharmacokinetic and pharmacodynamic interactions involving oseltamivir and chinese medicine.Evidence-based complementary and alternative medicine : eCAM · 2014Article
- Simultaneous quantification of prodrug oseltamivir and its metabolite oseltamivir carboxylate in human plasma by LC-MS/MS to support a bioequivalence study.Journal of pharmaceutical analysis · 2013Article
- Heat stabilization of blood spot samples for determination of metabolically unstable drug compounds.Bioanalysis · 2013Article
- Chemical analysis and transplacental transfer of oseltamivir and oseltamivir carboxylic acid in pregnant rats.PloS one · 2012Article
- Dried blood spot UHPLC-MS/MS analysis of oseltamivir and oseltamivircarboxylate--a validated assay for the clinic.Analytical and bioanalytical chemistry · 2011Article
- Pharmacologic considerations for oseltamivir disposition: focus on the neonate and young infant.Paediatric drugs · 2011Review
- Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.Clinical pharmacokinetics · 2010Review
- Pharmacokinetics of high-dose oseltamivir in healthy volunteers.Antimicrobial agents and chemotherapy · 2009Article
- The metabolism and transplacental transfer of oseltamivir in the ex vivo human model.Infectious diseases in obstetrics and gynecology · 2008Article
- Importance of collection tube during clinical studies of oseltamivir.Antimicrobial agents and chemotherapy · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
Abstract
The anti-influenza drug oseltamivir is an ester prodrug activated by hepatic carboxylesterases. Plasma esterases also convert up to 31.8% of the parent compound to the active metabolite after 4 h ex vivo, with wide interindividual variation. This source of error is removed by adding the esterase inhibitor dichlorvos to blood collection tubes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.